NNC 0174 0833

Drug Profile

NNC 0174 0833

Alternative Names: AM-833; NN-9838; NNC0174-0833

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novo Nordisk
  • Class Obesity therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Obesity

Most Recent Events

  • 01 Nov 2016 Novo Nordisk initiates a phase I trial for Obesity in USA (NCT02958085)
  • 01 Nov 2016 Novo Nordisk plans a phase I trial for Obesity in USA (NCT02958085)
  • 01 Mar 2016 Novo Nordisk completes a phase I trial for Obesity (In volunteers) in USA (NCT02300844)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top